natgillin/translations-raw huggingface dataset:
For more information concerning paediatric use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled. 
Za več informacij v zvezi s pediatrično uporabo zdravil, označenih z lutecijem (177Lu), glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo zdravila, ki bo radioaktivno označeno.
Radiopharmaceutical precursor, solution. 
Radionuklidni predhodnik, raztopina
The volume is 0.075 - 2 mL. 
in 1016 cm−2 s−1.
How the medicine radiolabelled with EndolucinBeta is used 
Kako se uporablja zdravilo, radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta
Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled. 
Glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo posameznega zdravila, ki bo radioaktivno označeno.
Red Marrow Osteogenic Cells Skin 
Osteogene celice 2,1500 Koža
What EndolucinBeta contains 
EndolucinBeta, kot bi smeli
It is recommended to add a binding agent such as DTPA prior to intravenous administration of Lutetium (177Lu)-labelled conjugates in order to form a complex with free Lutetium (177Lu), if present, leading to a rapid renal clearance of Lutetium (177Lu). 
DTPA, z namenom tvorjenja kompleksa s prostim lutecijem (177Lu), če je ta prisoten, saj tako povzročimo hitro izločanje lutecija (177Lu) prek ledvic.
Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been observed after treatment with Lutetium (177 Lu) peptide receptor radionuclide therapy for neuroendocrine tumours 
O raku kostnega mozga (mielodisplastičnem sindromu in akutni mieloični levkemiji) so pri bolnikih poročali več let po radionuklidni terapiji z lutecijem (177Lu) s peptidnimi receptorji za nevroendokrine tumorje.
Lungs 
Pljuča
EndolucinBeta is not intended for direct use in patients. 
Radionuklidni predhodnik EndolucinBeta ni namenjen za neposredno uporabo pri bolnikih.
Gamma 112.9498 
Nadledvične žleze 0,2130
Ovaries 
Vranica
Each 10 mL vial contains an activity ranging from 8 - 150 GBq, corresponding to 1.936 micrograms of Lutetium (177Lu), at ART. 
V eni 10-mililitrski viali je aktivnost v razponu od 8 do 150 GBq, kar ustreza 1,9-36 mikrogramom lutecija (177Lu) v času ART. Prostornina znaša 0,2-3,75 ml. Teoretična specifična aktivnost je 4.110 GBq/mg lutecija (177Lu).
Dry mouth has been reported among patients with prostate cancer receiving treatment with Lutetium (177Lu) and has been temporary. 
Pri bolnikih z rakom prostate, ki so bili zdravljeni z lutecijem (177Lu), so poročali o začasnem pojavu suhih ust.
There have been reports of extravasation of Lutetium (177Lu) labelled ligands in the post-marketing setting. 
V obdobju trženja zdravila so poročali o ekstravazaciji ligandov, označenih z lutecijem (177Lu).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING METALLIC CAN AND OUTER CARTON 
PODATKI NA ZUNANJI OVOJNINI KOVINSKA POSODA IN ZUNANJA ŠKATLA
Specific activity: …GBq/mg at ART 
PROSTORNINA: … ml AKTIVNOST: … GBq/vialo
After administration of the medicine radiolabelled with EndolucinBeta, you should 
Po prejemu zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, morate narediti naslednje.
Please refer to the package leaflet of the medicine that is to be radiolabelled with EndolucinBeta. 
Preberite navodilo za uporabo zdravila, ki bo radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta.
Myelosuppression 
Mielosupresija
1 mL of solution contains 40 GBq of Lutetium (177Lu) chloride at activity reference time (ART). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 ml raztopine vsebuje 40 GBq lutecijevega (177Lu) klorida v referenčnem času aktivnosti (ART
Gallbladder Wall LLI Wall 
Stena zgornjega dela debelega črevesa Srčna stena
What you need to know before the medicine radiolabelled with EndolucinBeta is used The medicine radiolabelled with EndolucinBeta must not be used 
Kaj morate vedeti, preden vam bodo dali zdravilo, radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta
Tumour lysis syndrome has been reported following Lutetium (177Lu) radioligand therapy. 
Po radioligandni terapiji z lutecijem (177Lu) so poročali o sindromu tumorske lize.
Skin and subcutaneous tissue disorders: Alopecia, described as mild and temporary, has been observed among patients receiving Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours. 
Bolezni kože in podkožja: Pri bolnikih, ki so prejemali radionuklidno terapijo z lutecijem (177Lu) s peptidnimi receptorji za nevroendokrine tumorje so opazili alopecijo, ki so jo opisovali kot blago in začasno.
The lower bound of the 95 % confidence interval of the reporting odds ratio for tumour lysis syndrome in EudraVigilance in association with Lu-177 is increased at 34.50, with 3 cases. 
Na osnovi 3 poročanih primerov v bazi EudraVigilance je spodnja meja 95-% intervala zaupanja razmerja obetov poročanja (reporting odds ratio - ROR) za sindrom tumorske lize v povezavi z Lu
OTHER 
Priželjc
Limits for radiochemical impurities should be set recognising the radiotoxicological potential of Lutetium (177Lu). 
upoštevanjem možne radiotoksičnosti lutecija (177Lu) je treba postaviti meje za radiokemijske nečistote.
B. PACKAGE LEAFLET 
PRILOGA II
The pharmacokinetic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled. 
Farmakokinetične lastnosti z lutecijem (177Lu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom EndolucinBeta pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označeno.
Radiation protection precautions in accordance with national regulations must therefore be taken. 
Zato je treba upoštevati nacionalne predpise glede previdnostnih ukrepov za zaščito pred ionizirajočimi sevanji.
EndolucinBeta should not be administered directly to the patient. 
Radionuklidni predhodnik EndolucinBeta se ne sme dajati neposredno bolniku.
The pharmacodynamic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled. 
Farmakodinamične lastnosti z lutecijem (177Lu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom EndolucinBeta pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označeno.
After neuroendocrine tumours are treated with Lutetium (177Lu), patients may experience symptoms associated with release of hormones from the tumour cells, known as a carcinoid crisis. 
Po zdravljenju nevroendokrinih tumorjev z lutecijem (177Lu) lahko bolniki doživijo simptome,
Adverse reactions following the administration of a Lutetium (177Lu)-labelled medicinal product prepared by radiolabelling with EndolucinBeta will be dependent on the specific medicinal product being used. 
4.8 Neželeni učinki Neželeni učinki po uporabi z lutecijem (177Lu) označenega zdravila, pripravljenega z radioaktivnim označevanjem z radionuklidnim predhodnikom EndolucinBeta, bodo odvisni od posameznega uporabljenega zdravila.
Dry mouth has been reported among patients with metastatic castration resistant prostate cancer receiving PSMA-targeted Lutetium (177Lu)-labelled radioligands and has been transient. 
Pri bolnikih z metastatskim na kastracijo odpornim rakom prostate, ki so prejemali z lutecijem (177Lu)
For information concerning special warnings and special precautions for use of Lutetium (177Lu)labelled medicinal products refer also to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled. 
Za informacije v zvezi s kontraindikacijami za posamezna zdravila, označena z lutecijem (177Lu) in pripravljena z radioaktivnim označevanjem z radionuklidnim predhodnikom EndolucinBeta, glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo posameznega zdravila, ki bo radioaktivno označeno.
Rest of Body 
Možgani Dojke
Metabolism and nutrition disorders: not known: Tumour lysis syndrome 
Neznana: sindrom tumorske lize
EndolucinBeta is not to be administered directly to patients. 
Radionuklidni predhodnik EndolucinBeta se ne sme dajati neposredno bolnikom.
Contact your nuclear medicine doctor if you have any questions. 
Če imate kakršna koli vprašanja, se posvetujte z zdravnikom nuklearne medicine.
If you are pregnant Medicines radiolabelled with EndolucinBeta must not be administered if you are pregnant. 
Zdravilo, radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta, se pri vas ne sme uporabiti:
The toxicological properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled. 
5.3 Predklinični podatki o varnosti Toksikološke lastnosti z lutecijem (177Lu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom EndolucinBeta pred dajanjem, bodo odvisne od zdravila, ki bo radioaktivno označeno.
Anaemia, thrombocytopenia, leucopenia, lymphopenia, and less commonly neutropenia may occur during radioligand therapy with Lutetium (177Lu). 
Pri radioligandni terapiji z lutecijem (177Lu) se lahko pojavi anemija, trombocitopenija, levkopenija,
1 mL of solution contains 40 GBq Lutetium (177Lu) chloride on activity reference time (ART), corresponding to 10 micrograms of Lutetium (177Lu) (as chloride). 
activity reference time), kar ustreza 10 mikrogramom lutecija (177Lu) (v obliki klorida).
EndolucinBeta has to be combined with a carrier medicine in a process called radiolabelling before administration. 
V postopku, imenovanem radioaktivno označevanje, je treba radionuklidni predhodnik EndolucinBeta pred dajanjem kombinirati z nosilnim zdravilom.
A. Before you start 
A. Preden začnete
Date of first authorisation: 14 January 2016 
Datum prve odobritve: 14. januar 2016
• Do not recycle. 
• Ne reciklirajte.
c Remission is defined as DAS <1.6. 
c Remisija je definirana kot DAS < 1,6.
Wash your hands with soap and water. 
Umijte si roke z milom in vodo.
Key results of studies 2, 3 and 4 are shown below. 
Ključni rezultati študij 2, 3 in 4 so prikazani spodaj
There may be new information. 
Morda bodo dodane nove informacije.
Other information (please complete) 
Druge informacije (izpolnite)
The healthcare professional's educational material should contain the following key elements: 
Izobraževalno gradivo za zdravstvene delavce mora vsebovati naslednje ključne elemente:
The absolute bioavailability is 76%. 
Absolutna biološka uporabnost 76 %.
The device will click a second time. 
Naprava še drugič klikne.
This is important to make the medicine easier and more comfortable to inject. 
To je pomembno, da se zdravilo lažje in udobneje injicira.
Do not warm in any other way. 
Raztopine ne segrevajte na noben drug način.
Find a well-lit, clean surface and gather all the equipment you need: 
Izberite čisto, dobro osvetljeno, ravno delovno površino in vse pripomočke, ki jih potrebujete:
Ask your doctor to record the dates and the results of your last screening for TB below: 
Zdravnika prosite, da spodaj zabeleži datume in rezultate vašega zadnjega presejanja za TB:
• The risk of opportunistic infections and tuberculosis (TB) 
• Tveganje za oportunistične okužbe in tuberkulozo (TB)
If you do not understand this information, please ask your doctor to explain it to you. 
Če teh informacij ne razumete, prosite zdravnika, da vam jih razloži.
Doctor's phone: 
Zdravnikov telefon:
Open 
odprite
After the second click, count slowly to 15 to make sure that the injection is complete. 
Po drugem kliku počasi štejte do 15, da zagotovite popolno injiciranje.
• if you or the child have an infection of any kind. 
• če imate vi ali otrok kakršno koli okužbo.
Responses of patients with psoriasis in studies 2, 3 and 4 
Odzivi bolnikov s psoriazo v študijah 2, 3 in 4
Clear or almost clear defined as 0 or 1 on a 0 to 5 scale. 
"Čisto" ali "skoraj čisto" definirano kot 0 ali 1 na lestvici od 0
The needle guard will completely cover the needle. 
Varnostni ščit igle bo iglo povsem prekrilo.
● You should be evaluated for tuberculosis (TB). 
● Pri vas je treba opraviti preizkus za tuberkulozo (TB).
b Values for Disease Activity Score (DAS) are means. 
b Vrednosti za oceno aktivnosti bolezni (DAS - Disease Activity Score) so povprečne vrednosti.
Please consult your doctor before you or the child receive any vaccines. 
Posvetujte se z zdravnikom, preden vi ali otrok prejmete katero koli cepivo.
● Show this card to any doctor involved in your or your child's treatment. 
● To kartico pokažite vsem zdravnikom, ki sodelujejo pri vašem zdravljenju ali zdravljenju vašega otroka.
SE = standard error a p = 0.0001 
SE = standard napaka a p = 0,0001
• Infections/monitoring: Tell your doctor of any recent travel outside the European region. 
• Okužbe/spremljanje: Povejte zdravniku za morebitno nedavno potovanje izven Evrope.
If you notice any of the following, you or the child may need urgent medical attention. 
Če opazite kar koli od naslednjega, boste vi ali vaš otrok morda potrebovali nujno zdravniško pomoč.
79 (75%)a sPGA “clear” or “minimal”, n (%) 
79 (75 %)a sPGA “čisto” ali “minimalno”, n (%)
Results: ● Please ask your physician to list your other medicines that may increase your risk of infection. 
Rezultati: ● Zdravnika prosite, da navede vsa druga zdravila, ki lahko povečajo tveganje za okužbo.
Etanercept is recommended for use in patients as defined in section 4.1. 
Uporaba etanercepta je priporočena pri bolnikih, kot je opredeljeno v poglavju 4.1.
Long-term experience with etanercept was generally comparable to the original 48-week study and did not reveal any new safety findings. 
Dolgoročne izkušnje z etanerceptom so v splošnem primerljive s prvotno 48-tedensko študijo in niso pokazale novih dognanj o varnosti.
The observed rates and incidences in these clinical trials were similar to those expected for the population studied. 
Ugotovljene stopnje in incidence v teh kliničnih preskušanjih so bile podobne tistim, ki so jih pričakovali za raziskovano populacijo.
The specific activity of etanercept is 1.7 × 106 units/mg. 
Specifična aktivnost etanercepta je 1,7 x 106 enot/mg.
Benepali is also prescribed for the treatment of the following diseases in children and adolescents. 
Zdravilo Benepali se predpisuje tudi za zdravljenje naslednjih bolezni pri otrocih in mladostnikih:
• if you or the child you are caring for, are allergic to etanercept or any of the other ingredients of Benepali (listed in section 6). 
• če ste vi ali otrok, za katerega skrbite, alergični na etanercept ali katero koli sestavino zdravila Benepali (navedeno v poglavju 6).
The youngest children (4 years of age) had reduced clearance (increased clearance when normalised by weight) compared with older children (12 years of age) and adults. 
Pri najmlajših otrocih (starih 4 leta) so opazili zmanjšan očistek (povečan, če je bil normaliziran s težo) v primerjavi s starejšimi otroki (starih 12 let) in odraslimi.
These antibodies have generally been non-neutralising and transient. 
Protitelesa na splošno niso bila nevtralizirajoča in so prehodna.
Dose and frequency of dosing for the child or adolescent will depend on body weight and disease. 
Odmerek in pogostnost odmerjanja za otroka ali mladostnika sta odvisna od njegove telesne mase in bolezni.
In adults (aged 18 and over), Benepali can be used for: 
Pri odraslih (starih 18 let in več) se zdravilo Benepali lahko uporablja za:
The osmolality of the solution is 325 ± 35 mOsm/kg. 
Osmolalnost raztopine je 325 ± 35 mOsm/kg.
Pull to open 
povlecite, da odprete
Not included in pack: • 1 alcohol swab, gauze pad and plaster 
Ni vključeno v pakiranju: • 1 alkoholni zloženec, gaza in obliž
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve PSUR za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
If you are injecting into the abdomen, choose a site that is at least 5 cm away from the belly button. 
Če injicirate v trebuh, izberite mesto, ki je vsaj 5 cm od popka.
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded (or stated) in the patient file. 
Z namenom izboljšanja sledljivosti bioloških zdravil je treba jasno zabeležiti (navesti) ime in številka serije uporabljenega zdravila v bolnikovo kartoteko.
Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. 
Priporočen so redni pregledi kože pri vseh bolnikih, še posebno pri tistih, ki imajo dejavnike tveganja za kožnega raka.
If you forget to inject Benepali 
Če ste si pozabili injicirati zdravilo Benepali
The doctor will provide you with detailed directions for preparing and measuring the appropriate dose. 
Zdravnik vam bo natančno pojasnil, kako boste pripravili in odmerili primeren odmerek.
When the syringe is empty, remove the needle from the skin at the same angle as inserted. 
Ko je brizga prazna, iglo izvlecite iz kože pod istim kotom, kot ste jo vstavili.
This appearance is normal for Benepali. 
Takšen izgled je normalen za zdravilo Benepali.
● Keep this card with you for 2 months after the last Benepali dose, since side effects may occur after your last dose of Benepali. 
● To kartico nosite pri sebi še 2 meseca po zadnjem odmerku zdravila Benepali, saj se lahko neželeni učinki pojavijo po vašem zadnjem odmerku zdravila Benepali.
a Patients who did not complete 12 months in the study were considered to be non-responders. 
a Bolniki, ki v študiji niso sodelovali 12 mesecev, so bili obravnavani kot neodzivni.
Allergic reactions have included angioedema and urticaria; serious reactions have occurred. 
Alergijske reakcije so vključevale angioedem in urtikarijo, pojavile so se resne reakcije.
Hepatitis B reactivation, listeria 
reaktivacija hepatitisa B, listeria
If an alternate dose is required, other etanercept products offering such an option should be used. 
Če je treba dati drugačen odmerek, je treba uporabiti druga zdravila z etanerceptom, ki to možnost omogočajo.
A total of 401 patients were enrolled, from which 203 were treated with etanercept. 
Sodeloval je 401 bolnik in od tega so bili 203 zdravljeni z etanerceptom.
Benepali is a medicine that is made from two human proteins. 
Zdravilo Benepali je pridobljeno iz dveh človeških beljakovin.
• Do not try to give yourself the injection unless your doctor or nurse has shown you how to give the injection. 
• Zdravila si ne poskušajte injicirati sami, če vas zdravnik ali medicinska sestra nista poučila o injiciranju.
● You should not use Benepali if you have an infection. 
● Zdravila Benepali ne smete uporabljati, če imate okužbo.
The use of etanercept in combination with other systemic therapies or phototherapy for the treatment of psoriasis has not been studied. 
Uporaba etanercepta v kombinaciji z drugimi sistemskimi zdravljenji ali fototerapijo za zdravljenje psoriaze ni raziskana.
Patient's name: 
Bolnikovo ime:
If you received Benepali during pregnancy, your baby may have a higher risk of getting an infection. 
Če ste med nosečnostjo prejeli zdravilo Benepali, lahko pri vašem dojenčku obstaja povečano tveganje za razvoj okužbe.
Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue Benepali therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Ker se imunoglobulini, tako kot mnoga druga zdravila, lahko izločajo v mleko pri človeku, se je treba odločiti med prenehanjem dojenja in prenehanjem zdravljenja z zdravilom Benepali, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
The safety and efficacy profiles of the two etanercept treatment regimens were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show comparability (non-inferiority) between the two regimens. 
Profil varnosti in učinkovitosti obeh režimov zdravljenja z etanerceptom je bil po 8 tednih primerljiv glede učinka na znake in simptome revmatoidnega artritisa; podatki po 16 tednih niso pokazali primerljivosti (neinferiornosti) med obema režimoma.
Tell your doctor or pharmacist if you or the child are taking, have recently taken or might take any other medicines (including sulfasalazine), even those not prescribed by your doctor. 
Obvestite zdravnika ali farmacevta, če vi ali vaš otrok jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo (vključno s sulfasalazinom), tudi če ga ni predpisal vaš zdravnik.
Etanercept treatment resulted in improvement in physical function during the double-blind period, and this benefit was maintained during the longer-term exposure of up to 2 years. 
Zdravljenje z etanerceptom je povzročilo izboljšanje telesne funkcije v dvojno slepem obdobju, ta koristni učinek pa se je ohranjal med dolgotrajnejšo izpostavljenostjo, ki je trajala do 2 leti.
Benepali may increase your risk of getting infections, which could be serious. 
Zdravilo Benepali lahko poveča tveganje za okužbe, ki so lahko resne.
To help you remember, it may be helpful to write in a diary which day(s) of the week Benepali should be used. 
Da si boste lažje zapomnili, vam bo morda pomagalo, če si v koledarju zabeležite dan (dneve) v tednu, ko morate uporabiti zdravilo Benepali.
In long-term (up to 34 months) open-label studies where etanercept was given without interruption, clinical responses were sustained and safety was comparable to shorter-term studies. 
V dolgoročnih (do 34 mesecev) odprtih študijah, v katerih so dajali etanercept brez prekinitev, so bili klinični odzivi trajni, varnost pa je bila primerljiva s tisto v krajših študijah.
Your doctor will determine the correct dose for the child and will prescribe an appropriate strength of etanercept. 
Natančen odmerek za otroka bo določil zdravnik in predpisal ustrezno jakost etanercepta.
The central volume of distribution of etanercept is 7.6 L, while the volume of distribution at steady-state is 10.4 L. 
Osrednji volumen porazdelitve etanercepta je 7,6 l, volumen porazdelitve v stanju dinamičnega ravnovesja pa je 10,4 l.
There have been reports of worsening of hepatitis C in patients receiving etanercept. 
Poročali so o poslabšanju hepatitisa C pri bolnikih, ki so prejemali etanercept.
The effect of etanercept on radiographic progression was maintained in patients who continued on treatment during the second year. 
Učinek etanercepta na radiografsko napredovanje bolezni se je ohranjal pri bolnikih, ki so nadaljevali zdravljenje še drugo leto.